Hydroxyurea enhances the activities of didanosine, 9-[2(phosphonylmethoxy)ethyl] adenine, and 9-[2(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates

被引：28

作者：

Palmer, S ^{[1
]}

Shafer, RW ^{[1
]}

Merigan, TC ^{[1
]}

机构：

[1] Stanford Univ, Med Ctr, Ctr AIDS Res, Stanford, CA 94305 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 08期

关键词：

D O I：

10.1128/AAC.43.8.2046

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We assessed the effects of hydroxyurea (HU) at a concentration of 50 mu M on the in vitro activities of 2',3'-dideoxyinosine (ddI), 9-[2-(phosphonylmethoxy)ethyl]adenine (PMEA), and 9-[2-(phosphonylmethoxy)propyl]adenine (PMPA) against a wild-type human immunodeficiency virus (HIV) type 1 (HIV-1) laboratory isolate and a panel of five well-characterized drug-resistant HIV isolates. Fifty micromolar HU significantly increased the activities of ddI, PMEA, and PMPA against both the wild-type and the drug-resistant HIV-1 isolates. In fixed combinations, both ddI and PMEA were synergistic with HU against wild-type and drug-resistant viruses.

引用

页码：2046 / 2050

页数：5

共 38 条

[1] PREFERENTIAL INCORPORATION OF NUCLEOSIDE ANALOGS AFTER TEMPLATE SWITCHING DURING HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE TRANSCRIPTION [J].

ARTS, EJ ;

WAINBERG, MA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :1008-1016

[2] 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE (PMEA) EFFECTIVELY INHIBITS RETROVIRUS REPLICATION INVITRO AND SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION IN RHESUS-MONKEYS [J].

BALZARINI, J ;

NAESENS, L ;

SLACHMUYLDERS, J ;

NIPHUIS, H ;

ROSENBERG, I ;

HOLY, A ;

SCHELLEKENS, H ;

DECLERCQ, E .

AIDS, 1991, 5 (01) :21-28

[3] Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl) guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice [J].

Balzarini, J ;

Vahlenkamp, T ;

Egberink, H ;

Hartmann, K ;

Witvrouw, M ;

Pannecouque, C ;

Casara, P ;

Nave, JF ;

DeClercq, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :611-616

[4]

BIANCHI V, 1986, J BIOL CHEM, V261, P6037

[5] Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals [J].

Biron, F ;

Lucht, F ;

Peyramond, D ;

Fresard, A ;

Vallet, T ;

Nugier, F ;

Grange, J ;

Malley, S ;

HamediSangsari, F ;

Vila, J .

ANTIVIRAL RESEARCH, 1996, 29 (01) :111-113

[6]

BIRON F, 1995, J ACQ IMMUN DEF SYND, V10, P36

[7] Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy [J].

DeAntoni, A ;

Foli, A ;

Lisziewicz, J ;

Lori, F .

JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (04) :899-903

[8] HIV INHIBITORS TARGETED AT THE REVERSE-TRANSCRIPTASE [J].

DECLERCQ, E .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) :119-137

[9]

DONEHOWER RC, 1992, SEMIN ONCOL, V19, P11

[10] ENHANCEMENT BY HYDROXYUREA OF THE ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POTENCY OF 2'-BETA-FLUORO-2',3'-DIDEOXYADENOSINE IN PERIPHERAL-BLOOD MONONUCLEAR CELLS [J].

GAO, WY ;

MITSUYA, H ;

DRISCOLL, JS ;

JOHNS, DG .

BIOCHEMICAL PHARMACOLOGY, 1995, 50 (02) :274-276

← 1 2 3 4 →